Researchers have tested the effectiveness of targeted chemotherapy paired with MRI-guided focused ultrasound (MRgFUS) in murine models of DIPG.
Following IV administration of doxorubicin, MRgFUS-treated animals exhibited a 4-fold higher concentration of drug within the SU-DIPG-17 brainstem tumours compared to controls. Moreover, the volumetric tumour growth rate was significantly suppressed in MRgFUS-treated animals whose tumours also exhibited decreased Ki-67 expression.
These data provide critical support for clinical trials investigating MRgFUS-mediated BBB opening, which may ameliorate DIPG chemotherapeutic approaches in children.
Ishida J, Alli S, Bondoc A, et al. MRI-guided focused ultrasound enhances drug delivery in experimental diffuse intrinsic pontine glioma. J. Control. Release (2020) https://doi.org/10.1016/j.jconrel.2020.11.010
A new synthetic protein nanoparticle capable of slipping past the nearly impermeable blood-brain barrier could deliver cancer-killing drugs directly to malignant brain tumors, new research from the University of Michigan shows.
The study is the first to demonstrate an intravenous medication that can cross the blood-brain barrier.
Gregory, J.V., Kadiyala, P., Doherty, R. et al. Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy. Nat Commun 11, 5687 (2020). https://doi.org/10.1038/s41467-020-19225-7
Midatech Pharma PLC announces encouraging results from a Phase I study at UCSF University in patients with DIPG. Sabine Mueller MD PhD, Principal Investigator of the study, said: "The study has determined a proposed dose range for MTX110 for Phase II and has shown that repeated delivery of MTX110 via CED is feasible and safe. In an upcoming Phase II study efficacy in this patient population will be assessed." MTX110 was administered directly into the tumour via a micro-catheter using convection enhanced delivery ("CED") with gadolinium-enhanced intra-operative MRI to guide and track drug distribution to the tumour.
A combination of lipid vesicles and ultrasound waves can provide highly specific drug delivery to target sites in rat brains. A recent research project from ETH Zurich (Switzerland) has demonstrated an application of sound waves in combination with newly developed lipid vesicles for drug delivery, which can target drugs to precise locations within the brain. The team need to continue testing the method in animals and are currently looking at its applications in the treatment of brain tumors and some mental illnesses, such as anxiety.
Chiesi validates the power of Bioasis technology to propel drugs across the blood-brain barrier (BBB). Scientists at Bioasis Technologies Inc have worked for over a decade to develop a technology – the patented xB3 platform – which helps small molecules shuttle across the BBB safely. The xB3 platform is a very versatile, high capacity delivery system able to deliver antibodies, enzymes, siRNA as well as small molecules across the BBB.
CarThera, a French company that designs and develops innovative ultrasound-based medical devices to treat brain disorders, today announces that it has been selected by the EIC Accelerator Pilot to receive a €2 million ($2.3M) grant and €10.5M ($12M) in equity for the development of its DOMEUS project for the treatment of glioblastoma (GBM) patients.
A novel drug delivery system by the global engineering technologies company, Renishaw, was successfully used as part of an extension study to a first-in-human clinical trial for the treatment of Parkinson’s disease. As one of the novel infusion regimes, neuroinfuse is currently only used in approved clinical trial settings. In order to eventually make the device generally available to patients, Renishaw is seeking academic, clinical, and industrial partners across a wide range of indications, from oncology to neurodegenerative diseases.